Ftse Mib
37.100,33
1,42%
DAX
21.902,42
1,63%
S&P 500
6.068,90
0,12%
NASDAQ
19.697,54
0,03%
Bitcoin
96.597,25
-0,02%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Iterum Therapeutics PLC (ITRM) Iterum Therapeutics PLC (ITRM) Notizie

ITRM

Iterum Therapeutics (ITRM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITRM
DataOraFonteTitoloSimboloCompagnia
31/01/202514:00GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025NASDAQ:ITRMIterum Therapeutics PLC
11/12/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
10/12/202413:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
21/11/202414:30GlobeNewswire Inc.Iterum Therapeutics Regains Full Nasdaq ComplianceNASDAQ:ITRMIterum Therapeutics PLC
14/11/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITRMIterum Therapeutics PLC
14/11/202413:00GlobeNewswire Inc.Iterum Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
11/11/202414:00GlobeNewswire Inc.Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024NASDAQ:ITRMIterum Therapeutics PLC
28/10/202410:00PR Newswire (US)Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
25/10/202417:03GlobeNewswire Inc.Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
10/10/202414:30GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2024NASDAQ:ITRMIterum Therapeutics PLC
09/10/202423:00GlobeNewswire Inc.Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual SummitNASDAQ:ITRMIterum Therapeutics PLC
30/09/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
10/09/202413:00GlobeNewswire Inc.Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult WomenNASDAQ:ITRMIterum Therapeutics PLC
06/09/202422:30GlobeNewswire Inc.Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment ConferenceNASDAQ:ITRMIterum Therapeutics PLC
14/08/202422:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
14/08/202413:00GlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
14/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ITRMIterum Therapeutics PLC
09/08/202423:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ITRMIterum Therapeutics PLC
07/08/202422:30GlobeNewswire Inc.Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:ITRMIterum Therapeutics PLC
06/08/202423:30GlobeNewswire Inc.Iterum Therapeutics Announces Expiration and Results of Rights OfferingNASDAQ:ITRMIterum Therapeutics PLC
02/08/202422:30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
02/08/202414:00GlobeNewswire Inc.Iterum Therapeutics Broadens Patent Estate for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
22/07/202413:30GlobeNewswire Inc.Iterum Therapeutics Commences Rights OfferingNASDAQ:ITRMIterum Therapeutics PLC
19/07/202423:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ITRMIterum Therapeutics PLC
17/07/202422:21Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ITRMIterum Therapeutics PLC
21/06/202414:00GlobeNewswire Inc.Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
07/06/202422:11Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ITRMIterum Therapeutics PLC
05/06/202414:00GlobeNewswire Inc.Iterum Therapeutics to Present Data at ASM Microbe 2024NASDAQ:ITRMIterum Therapeutics PLC
31/05/202414:00GlobeNewswire Inc.Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
13/05/202413:00GlobeNewswire Inc.Iterum Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITRM

La tua Cronologia

LSE
SDWD
Ish Wld Esg U-d
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci